Fluoropharma Medical Inc (PK:FPMI)
Business Focus: Biotechnology & Medical Research
Sep 27, 2018 09:00 am ET
FPMI Restructures CardioPET License With Massachusetts General Hospital
via NEWMEDIAWIRE -- FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has reached an agreement with The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to restructure its 2014 License Agreement...
Jun 25, 2018 01:33 pm ET
FPMI Acquires Exclusive Option to License Ground Fluor’s Advanced Neuronal PET imaging Agent
Fluoropharma Medical Inc. (OTCQB:FPMI) today announced that it has
acquired an exclusive option to license the meta-Fluorobenzylguanidine
(MFBG) imaging agent from Ground Fluor Pharmaceuticals, Inc. (GFP).
MFBG, labeled with the isotope Fluorine-18, can be used in conjunction
with Positron Emission Tomography (PET) for the assessment of neuronal
integrity. It may play an important role the diagnosis and assessment of
various cancers, as well as some aspects of cardiovascular disease.
Jan 10, 2018 05:06 pm ET
FluoroPharma Announces Closing of Stock Buyback Transaction
Montclair, NJ , Jan. 10, 2018 (GLOBE NEWSWIRE) -- FluoroPharma Medical Inc. (OTCQB: FPMI) today announced it completed the buyback of convertible preferred and common shares held by Platinum Long Term Growth VII, LLC, which is currently undergoing...
Oct 18, 2016 11:00 am ET
FluoroPharma and Philips Collaborate on Image Management for CardioPET Phase II Clinical Trial
FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has been collaborating with Philips for data management in conjunction with its Phase II clinical trials for its lead agent CardioPET (18-F FCPHA). Safety and image data from the...
Sep 26, 2016 12:15 pm ET
FluoroPharma Announces CardioPET Phase II Results at the 21st American Society of Nuclear Cardiology (ASNC) Meeting
FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that data from its Phase II clinical trial for CardioPET were presented at the 21st Annual Meeting of the American Society of Nuclear Cardiology on September 24th, 2016 in Boca Raton,...
Jun 17, 2016 02:07 pm ET
FluoroPharma Medical Announces Details for Investor Call on June 22, 2016
FluoroPharma Medical, Inc. (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:30 p.m. EDT on Wednesday, June 22, 2016. The objectives of the call are to provide updates on...
Jun 09, 2016 12:30 pm ET
FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals
FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has entered into a nonbinding letter of intent with Ground Fluor Pharmaceuticals, Inc. (GFP) to acquire GFP.The transaction is conditioned on the close of sufficient financing to fund...
Jun 06, 2016 09:50 am ET
FluoroPharma Enters Development and Commercialization Agreement for China and Canada
FluoroPharma Medical Inc. (OTCQB: FPMI) has entered an exclusive agreement with Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceutical Group, a pharmaceutical enterprise with a focus on critical therapeutic areas. With this...
May 25, 2016 09:39 am ET
FluoroPharma Medical Announces Acceptance of CardioPET Data for Presentation at the 21st Scientific Meeting of the American Society of Nuclear Cardiology
FluoroPharma Medical Inc., (OTCQB: FPMI) today announced the acceptance of the first comparative data from it's Phase II trial of CardioPET in subjects with a high likelihood of coronary artery disease (CAD). The abstract was accepted for oral...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.